HU-308

HU-308 is a drug that acts as a cannabinoid agonist. It is highly selective for the CB2 receptor subtype, with a selectivity of over 5000x for CB2 vs CB1.[1] The synthesis and characterization took place in the laboratory of Prof. Mechoulam at the Hebrew University of Jerusalem in the late 1990s. It has analgesic effects,[2] immunomodulatory properties in vitro,[3] promotes proliferation of neural stem cells,[4] and protects both liver and blood vessel tissues against oxidative stress via inhibition of TNF-α.[5][6]

HU-308
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H43O3
Molar mass415.638 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

United States

HU-308 is not scheduled at the federal level in the United States.[7]

Florida

"HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol)" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[8]

See also

References
  1. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. (December 1999). "HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor". Proceedings of the National Academy of Sciences of the United States of America. 96 (25): 14228–33. Bibcode:1999PNAS...9614228H. doi:10.1073/pnas.96.25.14228. PMC 24419. PMID 10588688.
  2. LaBuda CJ, Koblish M, Little PJ (December 2005). "Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain". European Journal of Pharmacology. 527 (1–3): 172–4. doi:10.1016/j.ejphar.2005.10.020. PMID 16316653.
  3. Saroz Y, Kho DT, Glass M, Graham ES, Grimsey NL (2019-10-19). "Cannabinoid Receptor 2 (CB 2 ) Signals via G-alpha-s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes". ACS Pharmacology & Translational Science. 2 (6): 414–428. doi:10.1021/acsptsci.9b00049. ISSN 2575-9108.
  4. Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzmán M, Galve-Roperh I (November 2006). "Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation". FASEB Journal. 20 (13): 2405–7. doi:10.1096/fj.06-6164fje. PMID 17015409.
  5. Rajesh M, Pan H, Mukhopadhyay P, Bátkai S, Osei-Hyiaman D, Haskó G, et al. (December 2007). "Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis". Journal of Leukocyte Biology. 82 (6): 1382–9. doi:10.1189/jlb.0307180. PMC 2225476. PMID 17652447.
  6. Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Huffman JW, et al. (October 2007). "CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion". American Journal of Physiology. Heart and Circulatory Physiology. 293 (4): H2210-8. doi:10.1152/ajpheart.00688.2007. PMC 2229632. PMID 17660390.
  7. 21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.
  8. Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.